Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
208.90
+6.44 (+3.18%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biogen Idec
< Previous
1
2
3
4
5
Next >
3 More Mid-Cap Biotechs The Street Sees Doubling
February 22, 2023
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk.
Via
MarketBeat
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
February 06, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
February 06, 2023
From
Biogen Inc.
Via
GlobeNewswire
Has The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure?
September 08, 2022
Finding the cure to Alzheimer’s has confounded researchers for decades.
Via
TheNewswire.com
Cassava Sciences Stock Undervalued with Its $124 Price Target?
January 30, 2023
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a
Via
MarketBeat
Exposures
Product Safety
Lecanemab Receives Priority Review Status in Japan
January 29, 2023
From
Biogen Inc.
Via
GlobeNewswire
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
January 26, 2023
From
Biogen Inc.
Via
GlobeNewswire
Biogen Names Priya Singhal as Executive Vice President, Head of Development
January 05, 2023
From
Biogen Inc.
Via
GlobeNewswire
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
January 04, 2023
From
Biogen Inc.
Via
GlobeNewswire
The Top Three Stocks Analysts Say To Buy
December 28, 2022
The analysts are rewarding companies that prove they can succeed in the face of headwinds and the most upgraded in Q4 2022 are Netflix, Biogen and Nike.
Via
MarketBeat
Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
December 19, 2022
From
Biogen Inc.
Via
GlobeNewswire
FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)
December 09, 2022
From
Biogen Inc.
Via
GlobeNewswire
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
December 06, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS
December 05, 2022
From
Biogen Inc.
Via
GlobeNewswire
CBOE's Weekly Market Recap: Nov.14-18 – Biogen’s Alzheimer’s Drug Captures Investors’ Attention
November 23, 2022
The market has experienced some relief from bearish price action in November, continuing October’s push to usher the SPDR S&P 500 ETF (NYSEARCA: SPY) toward $400.
Via
TheNewswire.com
Topics
ETFs
Economy
Stocks
Exposures
Interest Rates
US Equities
CONTINUED INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Continues to Investigate Biogen Inc.’s Directors and Officers for Breach of Fiduciary Duties – BIIB
November 17, 2022
From
Scott+Scott Attorneys at Law LLP
Via
Business Wire
Biogen Names Christopher Viehbacher President and Chief Executive Officer
November 10, 2022
Distinguished Industry Leader Brings Extensive International Experience in Large Pharmaceutical and Entrepreneurial Biotech Companies
From
Biogen Inc.
Via
GlobeNewswire
Is Biogen Stock a Buy Now That Guidance Has Been Raised?
October 26, 2022
Biogen stock (NASDAQ:BIIB) continues to get excellent news. On Tuesday, the pharmaceutical company released its third-quarter results, and for the first time in a long time, investors found something...
Via
PressReach
Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS
October 26, 2022
From
Biogen Inc.
Via
GlobeNewswire
New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS
October 26, 2022
From
Biogen Inc.
Via
GlobeNewswire
Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients
October 20, 2022
Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which...
Via
FinancialNewsMedia
Biogen's Stock Pullback Offers a Second Chance
October 18, 2022
Biogen is positioned to become more diversified over time. A diminishing risk profile combined with emerging growth prospects make the stock attractive.
Via
MarketBeat
Exposures
Product Safety
Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen
October 17, 2022
From
Biogen Inc.
Via
GlobeNewswire
GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY®
October 13, 2022
From
GoodRx
Via
Business Wire
MarketBeat: Week in Review 10/3-10/7
October 08, 2022
The jobs report is fueling a sell-off to end the week with more volatility on tap for next week. Here are some of the most popular articles from this week.
Via
MarketBeat
Topics
Economy
Electric Vehicles
Exposures
Electric Vehicles
Interest Rates
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
October 06, 2022
Here is a look at three names that buy-and-hold investors may want to consider as the race to find a cure for Alzheimer's disease accelerates
Via
MarketBeat
Exposures
Product Safety
Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
October 03, 2022
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)
September 30, 2022
From
Biogen Inc.
Via
GlobeNewswire
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Biogen Inc.’s Directors and Officers for Breach of Fiduciary Duties – BIIB
September 19, 2022
From
Scott+Scott Attorneys at Law LLP
Via
Business Wire
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
July 26, 2022
From
Biogen Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.